Literature DB >> 11727209

[Dysautonomic features in patients with Cuban type 2 spinocerebellar ataxia].

G Sánchez-Cruz1, L Velázquez-Pérez, L Gómez-Peña, E Martínez-Góngora, G Castellano-Sánchez, N Santos-Falcón.   

Abstract

INTRODUCTION: Dysautonomic features are the clinical signs and symptoms derived from anomalous functioning of the sympathetic or parasympathetic nervous systems in either the peripheral or central parts.
OBJECTIVE: To identify the clinical features related to dysautonomia in a patient with spinocerebellar ataxia with severe functional disability. PATIENTS AND METHODS: We studied a series of cases, including 21 patients with severe disability (confirmed to their bed or wheelchair, unable to walk and totally or partly dependent on other people for essential everyday activities). The patients and their families were closely questioned, and full clinical examination included a test for orthostasia.
RESULTS: All patients had some signs of peripheral dysautonomia: all had vasomotor disorders (orthostasia, distal pallor and coldness, Raynaud s phenomenon, etc.), 95.2% (constipation, urinary and rectal incontinence, polachuria, palpitations, tachycardia at rest, etc.), exocrine gland disorders in 71.4% (increased lachrymation, reduced sweating, increased or reduced salivation), 87.5% peripheral tissue nutrition disorders. Similarly, in all patients studied there was evidence of central dysautonomic disorder, with a syndrome of cachexia with bulimia, sleep disorders together with dysregulation of thirst and body temperature.
CONCLUSIONS: In patients with type 2 hereditary spinocerebellar ataxia with severe disability there was involvement of the peripheral and central nervous system regulating autonomic function.

Entities:  

Mesh:

Year:  2001        PMID: 11727209

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

1.  Early and severe autonomic failure: broadening the clinical phenotype of type-2 spinocerebellar ataxia. A case report.

Authors:  R Capozzo; G Rizzo; M De Mari; C Tortorella; G Logroscino
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

2.  Comprehensive study of early features in spinocerebellar ataxia 2: delineating the prodromal stage of the disease.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Edilia M Cruz-Rivas; Juan Fernández-Ruiz; Israel Vaca-Palomares; Jandy Lilia-Campins; Bulmaro Cisneros; Arnoy Peña-Acosta; Yaimeé Vázquez-Mojena; Rosalinda Diaz; Jonathan J Magaña-Aguirre; Tania Cruz-Mariño; Annelié Estupiñán-Rodríguez; José M Laffita-Mesa; Rigoberto González-Piña; Nalia Canales-Ochoa; Yanetza González-Zaldivar
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

Review 3.  Spinocerebellar ataxia 2 (SCA2).

Authors:  Isabel Lastres-Becker; Udo Rüb; Georg Auburger
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

4.  Non-motor and Extracerebellar Features in Spinocerebellar Ataxia Type 2.

Authors:  José Luiz Pedroso; Pedro Braga-Neto; Marcio Luiz Escorcio-Bezerra; Agessandro Abrahão; Marcus Vinicius Cristino de Albuquerque; Flavio Moura Rezende Filho; Paulo Victor Sgobbi de Souza; Wladimir Bocca Vieira de Rezende Pinto; Franklin Roberto Pereira Borges; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim; Orlando G P Barsottini
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

Review 5.  Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches.

Authors:  Luis C Velázquez-Pérez; Roberto Rodríguez-Labrada; Juan Fernandez-Ruiz
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

Review 6.  Nonmotor symptoms in spinocerebellar ataxias (SCAs).

Authors:  Adriana Moro; Mariana Moscovich; Marina Farah; Carlos Henrique F Camargo; Hélio A G Teive; Renato P Munhoz
Journal:  Cerebellum Ataxias       Date:  2019-08-27

7.  Ayurvedic approach in the management of spinocerebellar ataxia-2.

Authors:  Sarvesh Kumar Singh; Kshipra Rajoria
Journal:  Anc Sci Life       Date:  2016 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.